NO20055493L - 8β-vinyl-11β-(w-substituerte)alkyl-ostra-1,3,5(10)-triener - Google Patents

8β-vinyl-11β-(w-substituerte)alkyl-ostra-1,3,5(10)-triener

Info

Publication number
NO20055493L
NO20055493L NO20055493A NO20055493A NO20055493L NO 20055493 L NO20055493 L NO 20055493L NO 20055493 A NO20055493 A NO 20055493A NO 20055493 A NO20055493 A NO 20055493A NO 20055493 L NO20055493 L NO 20055493L
Authority
NO
Norway
Prior art keywords
vinyl
substituted
alkyl
estra
triene
Prior art date
Application number
NO20055493A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055493D0 (no
Inventor
Rolf Bohlmann
Olaf Peters
Nico Brauer
Alexander Hillisch
Hans-Peter Muhn
Margit Richter
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20055493D0 publication Critical patent/NO20055493D0/no
Publication of NO20055493L publication Critical patent/NO20055493L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20055493A 2003-04-22 2005-11-21 8β-vinyl-11β-(w-substituerte)alkyl-ostra-1,3,5(10)-triener NO20055493L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10318896A DE10318896A1 (de) 2003-04-22 2003-04-22 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene
PCT/EP2004/004086 WO2004094451A2 (de) 2003-04-22 2004-04-16 8beta-vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene

Publications (2)

Publication Number Publication Date
NO20055493D0 NO20055493D0 (no) 2005-11-21
NO20055493L true NO20055493L (no) 2006-01-18

Family

ID=33304956

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055493A NO20055493L (no) 2003-04-22 2005-11-21 8β-vinyl-11β-(w-substituerte)alkyl-ostra-1,3,5(10)-triener

Country Status (21)

Country Link
US (1) US7375098B2 (pt)
EP (1) EP1622924A2 (pt)
JP (1) JP2006524202A (pt)
KR (1) KR20060005386A (pt)
CN (1) CN100381457C (pt)
AR (1) AR044056A1 (pt)
AU (1) AU2004232462A1 (pt)
BR (1) BRPI0409794A (pt)
CA (1) CA2522354A1 (pt)
CL (1) CL2004000856A1 (pt)
CR (1) CR8053A (pt)
DE (1) DE10318896A1 (pt)
EA (1) EA009606B1 (pt)
EC (1) ECSP056180A (pt)
MX (1) MXPA05011386A (pt)
NO (1) NO20055493L (pt)
PE (1) PE20050423A1 (pt)
RS (1) RS20050793A (pt)
UY (1) UY28284A1 (pt)
WO (1) WO2004094451A2 (pt)
ZA (1) ZA200509447B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK14632002A3 (sk) * 2000-04-12 2003-03-04 Schering Aktiengesellschaft Substituované estratriény a ich použitie ako selektívne účinných estrogénov
BRPI0514974A (pt) 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
MX2007006653A (es) * 2005-10-05 2009-02-17 Sicor Inc Separacion de isomeros de fulvestrant.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226155B1 (de) * 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroide als selektiv wirksame estrogene
SK14632002A3 (sk) * 2000-04-12 2003-03-04 Schering Aktiengesellschaft Substituované estratriény a ich použitie ako selektívne účinných estrogénov
DE10151114A1 (de) * 2001-10-15 2003-04-17 Schering Ag 8ß-Substituierte-11ß-aryl-estra-2,3,5(10)-trienderivate

Also Published As

Publication number Publication date
EP1622924A2 (de) 2006-02-08
EA200501568A1 (ru) 2006-06-30
BRPI0409794A (pt) 2006-05-30
WO2004094451A2 (de) 2004-11-04
PE20050423A1 (es) 2005-08-13
CL2004000856A1 (es) 2005-03-28
EA009606B1 (ru) 2008-02-28
MXPA05011386A (es) 2006-04-18
ZA200509447B (en) 2009-08-26
JP2006524202A (ja) 2006-10-26
CA2522354A1 (en) 2004-11-04
KR20060005386A (ko) 2006-01-17
US7375098B2 (en) 2008-05-20
CN1777618A (zh) 2006-05-24
AR044056A1 (es) 2005-08-24
WO2004094451A3 (de) 2004-12-23
US20050065135A1 (en) 2005-03-24
AU2004232462A1 (en) 2004-11-04
CN100381457C (zh) 2008-04-16
NO20055493D0 (no) 2005-11-21
ECSP056180A (es) 2006-04-19
DE10318896A1 (de) 2004-11-25
CR8053A (es) 2006-05-29
RS20050793A (sr) 2008-04-04
UY28284A1 (es) 2004-11-30

Similar Documents

Publication Publication Date Title
Ari et al. Palladium (II) saccharinate complexes with bis (2-pyridylmethyl) amine induce cell death by apoptosis in human breast cancer cells in vitro
Ofir et al. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent
BRPI0407446A (pt) Anticorpos para c-met para o tratamento de cânceres
NO20023934D0 (no) Nye forbindelser
Xie et al. Capsaicin and dihydrocapsaicin induce apoptosis in human glioma cells via ROS and Ca2+‑mediated mitochondrial pathway
IS6658A (is) Ný efnasambönd
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
SE9902987D0 (sv) Novel compounds
KR20160045079A (ko) 질환의 치료를 위한 ｋｄｍ１ａ 저해인자
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
BR0308030A (pt) Derivados de 5-feniltiazol e uso como inibidores de pi3 cinase
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
JP2010502644A (ja) Ｗｒｎ結合分子を用いる治療方法
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BR0007589A (pt) Inibidores da proliferação de células
DK1206484T3 (da) Antipicornavirale forbindelser og sammensætninger, deres farmaceutiske anvendelser og materialer til deres syntese
Zhou et al. Taxifolin inhibits the development of scar cell carcinoma by inducing apoptosis, cell cycle arrest, and suppression of PI3K/AKT/mTOR pathway
Lei et al. Design, synthesis, and biological evaluation of novel evodiamine derivatives as potential antihepatocellular carcinoma agents
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
Soleimani et al. High cytotoxicity and apoptotic effects of natural bioactive benzofuran derivative on the MCF-7 breast cancer cell line
NO20062679L (no) Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
Gao et al. Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells
Wang et al. Targeting procaspase‐3 with WF‐208, a novel PAC‐1 derivative, causes selective cancer cell apoptosis
SE9804212D0 (sv) Compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application